Bristol-Myers Squibb - Company & Market Research Reports

Home /
Companies /
Bristol-Myers Squibb

Bristol-Myers Squibb is a pharmaceutical company that develops products for various diseases, such as oncology, virology, cardiovascular diseases, serious mental illness, and immunoscience. The company has delivered 12 new medicines to patients in the past 7 years. It also provides products for Alzheimer's disease, atherosclerosis/thrombosis, hepatitis, HIV/AIDS, solid organ transplant rejection, and a wide variety of other diseases and disorders. Bristol-Myers Squibb was founded in 1990 and is based in Uxbridge, United Kingdom.

REFINE BY

KEYWORD

CATEGORIES

Oncology Drugs 480
Immune Disorders Drugs 201
Drug Discovery 169
Cardiovascular Drugs 159
Infectious Diseases Drugs 138
Biopharmaceuticals 133
Clinical Trials 126
Endocrine and Metabolic Disorders Drugs 110
Central Nervous System Drugs 100
Pharmaceuticals 95
Musculoskeletal Disorders Drugs 94
Leukemia Drugs 84
Hematological Drugs 83
Liver and Kidney Disorders Drugs 81
Lymphoma Drugs 62
Dermatological Drugs 55
Diabetes Drugs 54
Skin Cancer Drugs 51
Brain Cancer Drugs 45
Respiratory Drugs 44
Gastrointestinal Drugs 41
Mental Disorders Drugs 41
Lung Cancer Drugs 39
Pharmaceutical Intermediates 38
Drug Delivery 37
Immunosuppressive Drugs 34
Pharmaceutical Manufacturing 33
Infusions and Injectables 30
Liver Cancer Drugs 28
Bladder Cancer Drugs 25
Analgesics 25
Drugs by Therapeutic Area 24
Antibiotics 23
Kidney Cancer Drugs 22
Colon Cancer Drugs 20
HIV/AIDS Drugs 20
Prostate Cancer Drugs 18
Pancreatic Cancer Drugs 18
Schizophrenia Drugs 18
Urological Disorders Drugs 17
Sexual and Reproductive Health Drugs 15
Ovarian Cancer Drugs 14
Cervical Cancer Drugs 14
Breast Cancer Drugs 13
Cancer Vaccines 13
Thyroid Cancer Drugs 12
Psoriasis Drugs 12
Generic Drugs 10
Biosimilars and Biosuperiors 10
Over the Counter (OTC) Drugs 9
Vaccines 9
Transdermal and Transmucosal Drug Delivery 8
Anti-Obesity Drugs 8
Optical Disorders Drugs 7
Alzheimer's Disease Drugs 7
Uterine Cancer Drugs 6
Company Reports 5
Anxiety Drugs 4
Pharmacoeconomics 3
Cough and Cold Drugs 3
Vitamins and Dietary Supplements 3
Addiction Disorders Drugs 2
Animal Pharmaceuticals 2
Asthma Drugs 2
Inhalers and Nebulisers 1
Anesthetic Drugs 1
Allergy Drugs 1
Bronchitis Drugs 1

SHOW ALL

REPORT TYPE

All Reports

Company Reports

Market Reports

Google Reviews

4.8



276 reviews

2,461 Results (Page 113 of 124)
- Relevance
  Sort by

Adrenocortical Carcinoma - Pipeline Insight, 2024

 Clinical Trials
April 2024
60 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

Clear Cell Sarcoma - Pipeline Insight, 2024

 Clinical Trials
April 2024
40 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

Paranasal sinus cancer - Pipeline Insight, 2024

 Clinical Trials
April 2024
40 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

Kaposi's sarcoma - Pipeline Insight, 2024

 Clinical Trials
April 2024
40 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

Neuroblastoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update

 Report
January 2023
393 Pages
Global

From

€4896EUR$5,000USD£4,072GBP

NEED HELP FINDING THE RIGHT PRODUCT? Farid will help you find what you are looking for.

Call: 1-800-526-8630 ASK A QUESTION REQUEST A CALL BACK

Mycosis Fungoides Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update

 Report
January 2023
201 Pages
Global

From

€4896EUR$5,000USD£4,072GBP

Addison's Disease treatment Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

 Report
August 2022
120 Pages
Global

From

€4651EUR$4,750USD£3,868GBP

Lysophosphatidic Acid Receptor 1 Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

 Report
November 2023
83 Pages
Global

From

€3500EUR$3,829USD£3,013GBP

Liver Fibrosis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

 Report
December 2022
220 Pages
Global

From

€2448EUR$2,500USD£2,036GBP

Autacoids and Related Drugs Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Product Type

 Report
October 2023
88 Pages
Global

From

€3500EUR$3,829USD£3,013GBP

Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type (Immunotherapy, Chemotherapy, and Targeted Therapy), By Route of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2022 - 2028

 Report
November 2022
206 Pages
Global

From

€3525EUR$3,600USD£2,932GBP

Cancer Therapeutics and Biotherapeutic Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

 Report
October 2024
84 Pages
Global

From

€3500EUR$3,829USD£3,013GBP

Transitional Cell Cancer Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

 Report
October 2024
88 Pages
Global

From

€3500EUR$3,829USD£3,013GBP

Malignant Mesothelioma Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

 Report
October 2024
108 Pages
Global

From

€3500EUR$3,829USD£3,013GBP

Human Chorionic Gonadotropin Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

 Report
October 2023
77 Pages
Global

From

€3500EUR$3,829USD£3,013GBP

Galectin Inhibitor - Pipeline Insight, 2024

 Clinical Trials
January 2024
60 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

T Cell Inhibitor - Pipeline Insight, 2024

 Clinical Trials
January 2024
60 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

CCR1 Inhibitor - Pipeline Insight, 2024

 Clinical Trials
January 2024
60 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

Non-Receptor Tyrosine Kinase Inhibitor - Pipeline Insight, 2024

 Clinical Trials
January 2024
60 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

Bcr-Abl Tyrosine Kinase Inhibitor - Pipeline Insight, 2024

 Clinical Trials
January 2024
60 Pages
Global

From

€857EUR$875USD£713GBP

€1224EUR$1,250USD£1,018GBP

2,461 Results (Page 113 of 124)
- 1
- 111
- 112
- 113
- 114
- 115

ASK A QUESTION

An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net

*Required Information

Name*

Email Address* Please provide your business or academic email address.

Country*

Phone Number*

Your Question*

I have read Research and Markets' Privacy Policy and consent to the processing of my personal data.

We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.